Dominant Firms’ Duties to Deal with Pharmaceutical Parallel Traders Following Glaxo Greece
Louise Macnab, Robert O’Donoghue, Apr 15, 2009
EU competition policy on dominant firms and pharmaceutical parallel trade wholesalers taking advantage of arbitrage possibilities to export drugs from a low-priced Member State to a higher-priced one reminds one of a debate between two famous economists. Each of them had taken opposing sides in a case and, after several discussions, they each remained wholly unpersuaded of the others view. In a fit of exasperation, one economist said to the other I agree with you, but you are completely wrong! So it is with parallel trade. The virtuous wholesalers say that they bring much-needed price competition to the (higher-priced) market. The no-less-virtuous pharmaceutical companies say that this is true, if at all, only in the short term, and that it comes at the expense of appropriation of manufacturer profits that fund expensive research & development (R&D) so there is, they say, less competition in the medium- to long-term. Both may be correct, for different reasons and from different perspectives.
Links to Full Content
Featured News
Court Dismisses Monopoly Claims Against Tempur Sealy
Oct 18, 2024 by
CPI
Philadelphia City Council Advances Legislation to Tackle Rent Price-Fixing
Oct 17, 2024 by
CPI
FTC Probes Deere for Potential Anti-Competitive Repair Practices
Oct 17, 2024 by
CPI
Britain’s Ofcom to Outline Strict Guidelines for Tackling Illegal Online Content
Oct 17, 2024 by
CPI
EU Considers Expanding Potential Fines for X, Targeting Musk’s Broader Business Empire
Oct 17, 2024 by
CPI
Antitrust Mix by CPI
Antitrust Chronicle® – Refusal to Deal
Sep 27, 2024 by
CPI
Antitrust’s Refusal-to-Deal Doctrine: The Emperor Has No Clothes
Sep 27, 2024 by
Erik Hovenkamp
Why All Antitrust Claims are Refusal to Deal Claims and What that Means for Policy
Sep 27, 2024 by
Ramsi Woodcock
The Aspen Misadventure
Sep 27, 2024 by
Roger Blair & Holly P. Stidham
Refusal to Deal in Antitrust Law: Evolving Jurisprudence and Business Justifications in the Align Technology Case
Sep 27, 2024 by
Timothy Hsieh